top of page

Scribe Biosciences Selected to Participate in the BioTools Innovator Accelerator. Recognized as one of the best in class startups for life science tools

San Francisco, CA – May 22, 2023 -  Scribe Biosciences, a company developing technologies to study cell-to-cell interactions in a microenvironment, has announced that is has been selected as one of 19 companies to participate in the 2023 BioTools Innovator Accelerator. The BioTools Innovator Accelerator is part of the MedTech Innovator which is the largest life science accelerator in the world working with the best-in-class startups to advance cutting-edge research and improve human health.


The four-month program provides peer-to-peer mentorship, a customized educational curriculum, and access to funding. Each year, accelerator companies compete for a grand prize of $250,000 for the title of BioTools Innovator of the Year. Success rates are high with the overall program.  In Q1 2023, approximately 30% of all funds raised in the medtech sector went to graduates of the MedTech Innovator.


Scribe Biosciences MOD technology that builds precise droplet-based cell assays through
deterministic assembly of cells and reagents is a natural fit for the accelerator. Novel workflows
for cytotoxicity assays for cell therapy and functional screening for plasma B cells for antibody
discovery are just two of the high-value workflows currently being developed.

“We launched BioTools Innovator to fill a gap in the life sciences industry where promising technologies falter due to lack of sophisticated guidance that prevents entrepreneurs from making avoidable mistakes,” said Kathryn Zavala, managing director of the organization. “These companies represent the next frontier of innovative technologies that will help us develop solutions to diagnose and treat diseases more effectively and live healthier.”


About BioTools Innovator

BioTools Innovator was established three years ago to advance leading research to improve human health by speeding up the growth of a wide range of life sciences tools and diagnostics. It provides mentorship and support by matching industry leaders with innovative early-stage and emerging-growth biotechnology companies. To learn more, go to:


About Scribe Biosciences

Scribe Biosciences is a San Francisco-based company pioneering technologies to accelerate immunotherapy discoveries through linked functional and genomic profiling of single-cell interactions. Scribe's Microenvironment on Demand (MOD) technology enables the construction of hundreds of thousands of live cell-based assays (cytotoxicity, secretion) in droplets and selectively profile assay-positive droplets using genomics readouts. Scribe’s platform will enable a deeper understanding of cancer, cardiovascular, and autoimmune diseases by linking live-cell assays to genomics at a single-cell resolution. To learn more, go to:


Russell Cole, co-founder and CEO

bottom of page